Hyaluronan in cancer - Pathophysiology and pharmacotherapy perspectives;Hialuronian w chorobach nowotworowych - Patofizjologia i perspektywy farmakoterapii

Nowotwory

Volumn 61, Issue 4, 2011, Pages 380-395

  Karbownik, Michał S ^a   Nowak, Jerzy Z ^a  

^a Katedra Farmakologii i Farmakologii Klinicznej   (Poland)

Author keywords

Anticancer drugs; Cancerogenesis; CD44; Hyaluronan; Hyaluronic acid; Nanocarriers; RHAMM

Indexed keywords

ANTINEOPLASTIC AGENT; CELL RECEPTOR; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIC ACID BINDING PROTEIN; HYALURONIC ACID DERIVATIVE; NANOCARRIER; SMALL INTERFERING RNA;

ARTICLE; CANCER IMMUNIZATION; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOPHYSIOLOGY;

EID: 80855141826     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (179)

1. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-39. (Pubitemid 38868622)
2. Nowak JZ. Hialuronian: aspekty biochemiczne i funkcjonalne. Mag Lek Okul 2010;4:37-49.
3. Laurent TC, Fraser JR: Hyaluronan. FASEB J 1992;6:2397-404.
4. Scott JE, Cummings C, Brass A i wsp. Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowingelectron microscopy and computer simulation. Hyaluronan is a very efficient network-forming polymer. Biochem J 1991;274:699-705.
5. Laurent TC. Hyaluronan research in Uppsala. Ups J Med Sci 2007;112:123-42.
6. Jóźwiak-Bȩbenista M, Nowak JZ. Hialuronian: charakterystyka i praktyczne zastosowanie w medycynie. Farm Pol 2010;66:882-93.
7. Prehm P. Hyaluronate is synthetized at plasma membranes. Biochem J 1984;220:597-600.
8. De Angelis PL. Hyaluronan synthases: fascinating glycosyltransferases from vertebrates, bacterial pathogens, and algal viruses. Cell Mol Life Sci 1999;56:670-82.
9. Itano N, Kimata K. Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol 2008;18:268-74.
10. Spicer AP, Seldin MF, Olsen AS i wsp. Chromosomal localization of the human and mouse hyaluronan synthase genes. Genomics 1997;41:493-7. (Pubitemid 27194808)
11. Itano N, Sawai T, Yoshida M i wsp. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999;274:25085-92.
12. Spicer AP, Tien JY. Hyaluronan and morphogenesis. Birth Defects Res C Embryo Today 2004;72:89-108. (Pubitemid 38456573)
13. Camenisch TD, Spicer AP, Brehm-Gibson T i wsp. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 2000;106:349-60. (Pubitemid 30655635)
14. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007;23:435-61.
15. Wilkinson TS, Potter-Perigo S, Tsoi C i wsp. Pro-and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts. Am J Respir Cell Mol Biol 2004;31:92-9. (Pubitemid 38888044)
16. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:3-14. (Pubitemid 40246722)
17. Stern R, Jedrzejas MJ. The hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006;106:818-39.
18. Csoka AB, Scherer SW, Stern R. Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics 1999;60:356-61. (Pubitemid 29471502)
19. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001;20:499-508. (Pubitemid 33109098)
20. Lepperdinger G, Mullegger J, Kreil G. Hyal2-less active, but more versatile? Matrix Biol 2001;20:509-14.
21. Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem 1998;273:22466-70. (Pubitemid 28399812)
22. Cherr GN, Yudin AI, Overstreet JW. The dual functions of GPIanchored PH-20: hyaluronidase and intracellular signaling. Matrix Biol 2001;20:515-25. (Pubitemid 33109100)
23. Beech DJ, Madan AK, Deng N. Expression of PH-20 in normal and neoplastic breast tissue. J Surg Res 2002;103:203-7. (Pubitemid 34948502)
24. Stern R, Kogan G, Jedrzejas MJ i wsp. The many ways to cleave hyaluronan. Biotechnol Adv 2007;25:537-57. (Pubitemid 47464847)
25. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006;85:699-715 (Pubitemid 44070579)
26. Krasiński R, Tchórzewski H. Hialuronian jako czynnik reguluja̧cy proces zapalenia. Postȩpy Hig Med Dośw 2007;61:683-9.
27. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris) 2005;53:372-82. (Pubitemid 41112071)
28. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011;91:221-64.
29. Screaton GR, Bell MV, Jackson DG i wsp. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-4. (Pubitemid 23004805)
30. Naor D, Nedvetzki S, Golan I i wsp. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79. (Pubitemid 35425379)
31. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. (Pubitemid 36077255)
32. Bajorath J. Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 2000;39:103-11. (Pubitemid 30176478)
33. Eshkar-Sebban L, Ronen D, Levartovsky D i wsp. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J Immunol 2007;179:1225-35.
34. Lesley J, English N, Perschl A i wsp. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J Exp Med 1995;182:431-7.
35. Johnson P, Ruffell B. CD44 and its role in inflammation and inflammatory diseases. Inflamm Allergy Drug Targets 2009;8:208-20.
36. Heldin P, Karousou E, Bernert B i wsp. Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connect Tissue Res 2008;49:215-8.
37. Zaman A, Cui Z, Foley JP i wsp. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am J Respir Cell Mol Biol 2005;33:447-54. (Pubitemid 41572687)
38. Tolg C, Hamilton SR, Nakrieko KA i wsp. Rhamm-/-fibroblasts are defective in CD44-mediated ERK1, 2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 2006;175:1017-28. (Pubitemid 44969206)
39. Tolg C, Hamilton SR, Nakrieko KA i wsp. Rhamm-/-fibroblasts are defective in CD44-mediated ERK1, 2 motogenic signaling, leading to defective skin wound repair. J Cell Bioll 2006;175:1017-28. (Pubitemid 44969206)
40. Tolg C, Hamilton SR, Morningsar L i wsp. RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem 2010;285:26461-74.
41. Tsan M F, Gao B. Endogenous ligands of Toll-like receptors. Biochem Biophys Res Commun 2004;317:1149-54.
42. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003;13:1-7. (Pubitemid 36120543)
43. Harris EN, Weigel JA, Weigel PH. The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J Biol Chem 2008;283:17341-50.
44. Yeatman TJ, Nicolson GL. Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol 1993;9:256-63. (Pubitemid 23154465)
45. Toole B P. Hyaluronan promotes the malignant phenotype. Glycobiology 2002;12:37R-42R. (Pubitemid 34567859)
46. Toole B P, Hascall VC. Hyaluronan and tumor growth. Am J Pathol 2002;161:745-7. (Pubitemid 34988359)
47. Stern R. Hyaluronan in cancer biology. Semin Cancer Biol 2008;18:237. (Pubitemid 351794538)
48. Paiva P, Van Damme M P, Tellbach M i wsp. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol Oncol 2005;98:193-202. (Pubitemid 41019105)
49. Theocharis AD, Vynios DH, Papageorgakopoulou N i wsp. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003;35:376-90. (Pubitemid 36084460)
50. Itano N, Zhuo L, Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 2008;99:1720-5.
51. Alaniz L, Garcia M, Rizzo M i wsp. Altered hyaluronan biosynthesis and cancer progression: an immunological perspective. Mini Rev Med Chem 2009;9:1538-46.
52. Manley G, Warren C. Serum hyaluronic acid in patients with disseminated neoplasm. J Clin Pathol 1987;40:626-30. (Pubitemid 17092843)
53. Wilkinson CR, Bower LM, Warren C. The relationship between hyaluronidase activity and hyaluronic acid concentration in sera from normal controls and from patients with disseminated neoplasm. Clin Chim Acta 1996;256:165-73. (Pubitemid 27055805)
54. Xing RD, Chang SM, Li JH i wsp. Serum hyaluronan levels in oral cancer patients. Chin Med J (Engl) 2008;121:327-30.
55. Toole B P, Zoltan-Jones A, Misra S i wsp. Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs 2005;179:66-72. (Pubitemid 40976290)
56. Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006;66:10233-7. (Pubitemid 44799736)
57. Park JB, Kwak HJ, Lee SH. Role of hyaluronan in glioma invasion. Cell Adh Migr 2008;2:202-7.
58. Misra S, Hascall VC, Berger FG i wsp. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res 2008;49:219-24.
59. Perrotta R, Bevelacqua Y, Malaguarnera G i wsp. Serum markers of cutaneous melanoma. Front Biosci (Elite Ed) 2010;2:1115-22.
60. Grigoriu BD, Grigoriu C, Chahine B i wsp. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 2009;71:31-8.
61. Dickinson LE, Gerecht S. Micropatterned surfaces to study hyaluronic acid interactions with cancer cells. J Vis Exp 2010;46:doi: 10.3791/2413.
62. Bourguignon LY W, Zhu H, Zhou B i wsp. Hyaluronan (HA) promotes CD44v3-Vav2 interaction with Grb2-p185HER2 and induces Rac1 & Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 2001;276:48679-92.
63. Auvinen P, Tammi R, Tammi M i wsp. Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005;47:420-8. (Pubitemid 41428491)
64. Bourguignon L Y W, Singleton P, Zhu H i wsp. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho-kinase promotes Grb2-associated binding-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003;278:29420-34. (Pubitemid 36962321)
65. Da Cunha CB, Oliveira C, Wen X i wsp. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest 2010 Sep. 20, w druku.
66. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997;186:1985-96. (Pubitemid 28013682)
67. Cichy J, Pure E. The liberation of CD44. J Cell Biol 2003;161:839-43. (Pubitemid 36718417)
68. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004;95:930-5. (Pubitemid 40089583)
69. Stern R, Shuster S, Neudecker BA i wsp. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 2002;276:24-31. (Pubitemid 34948348)
70. Stern R, Shuster S, Wiley TS i wsp. Hyaluronidase can modulate expression of CD44. Exp Cell Res 2001;266:167-76. (Pubitemid 32989053)
71. Yaqub S, Aandahl EM. Inflammation versus adaptive immunity in cancer pathogenesis. Crit Rev Oncog 2009;15:43-63.
72. Bourguignon L Y W. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008;18:251-9.
73. Zhu D, Bourguignon L Y W. The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation. Cell Motil Cytoskeleton 1998;39:209-22. (Pubitemid 28136563)
74. Zhu D, Bourguignon L Y W. Interaction between CD44 and the repeat domain of ankyrin promotes hyaluronic acid-mediated ovarian tumor cell migration. J Cell Physiol 2000;183:182-95. (Pubitemid 30185937)
75. Bourguignon L Y W, Gilad E, Brightman A i wsp. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 2006;281:14026-40. (Pubitemid 43848329)
76. Mishra JP, Mishra S, Gee K i wsp. Differential involvement of calmodulin-dependent protein kinase II-activated AP-1 and c-Jun. N-terminal kinase-activated EGR-1 signaling pathways in tumor necrosis factor-alpha and lipopolysaccharide-induced CD44 expression in human monocytic cells. J Biol Chem 2005;280:26825-37. (Pubitemid 41040716)
77. 2+/calmodulin-dependent protein kinase mediates the phosphorylation of CD44 required for cell migration on hyaluronan. Biochem J 2001;357:843-50. (Pubitemid 32735165)
78. Corbett KD, Alber T. The many faces of Ras: Recognition of small GTP-binding proteins. Trends Biochem Sci 2001;26:710-16. (Pubitemid 34019167)
79. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001;114:2713-22. (Pubitemid 32785451)
80. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004;279:26991-7007. (Pubitemid 38812535)
81. Katso R, Okkenhaug K, Ahmadi K i wsp. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-75. (Pubitemid 33096187)
82. Bourguignon L Y W, Zhu H, Shao L i wsp. CD44 interaction with Tiam1 promotes Rac1 signaling and hyaluronic acid (HA)-mediated breast tumor cell migration. J Biol Chem 2000;275:1829-38. (Pubitemid 30060806)
83. Bourguignon L Y W, Zhu H, Shao L i wsp. Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol 2000;150:177-91. (Pubitemid 30480236)
84. Nowak JM, Grzanka A, Żuryń A i wsp. Rodzina białek Rho i ich rola w cytoszkielecie komórki. Postȩpy Hig Med Dośw 2008;62:110-17.
85. Bourguignon L Y W, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem 2007;282:19426-41. (Pubitemid 47100114)
86. Mataraza JM, Briggs MW, Li Z i wsp. IQGAP1 promotes cell motility and invasion. J Biol Chem 2003;278:41237-45. (Pubitemid 37280951)
87. Orian-Rousseau V, Chen L, Sleeman JP i wsp. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-86. (Pubitemid 35424194)
88. Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005;280:8875-83. (Pubitemid 40409577)
89. Casalini P, Iorio MV, Galmozzi E i wsp. Role of HER receptors family in development and differentiation. J Cell Physiol 2004;200:343-50. (Pubitemid 39006925)
90. Ghatak S, Hascall VC, Markwald RR i wsp. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J Biol Chem 2010;285:19821-32.
91. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87. (Pubitemid 41058349)
92. Kumar S, Masood N, Shaikh AJ. Old disease, new targets-part-I, solid malignancies. J Pak Med Assoc 2009;59:398-405.
93. Bartolazzi A, Peach R, Aruffo A i wsp. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66. (Pubitemid 24181055)
94. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991;174:859-66.
95. Carvalho R, Milne AN, Polak M i wsp. A novel region of amplification at 11p12-13 in gastric cancer, revealed by representational difference analysis, is associated with overexpression of CD44v6, especially in early-onset gastric carcinomas. Genes Chromosomes Cancer 2006;45:967-75. (Pubitemid 44360184)
96. Hong SC, Song JY, Lee JK i wsp. Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res 2006;32:379-86.
97. Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck 2007;29:550-8. (Pubitemid 47324771)
98. Kuo KT, Liang CW, Hsiao CH i wsp. Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol 2006;19:1570-7.
99. Lopez JI, Camenisch TD, Stevens MV i wsp. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005;65:6755-63. (Pubitemid 41060713)
100. Gao AC, Lou W, Dong JT i wsp. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-9. (Pubitemid 27098007)
101. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007;6:18.
102. Patrawala L, Calhoun-Davis T, Schneider-Broussard R i wsp. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796-805. (Pubitemid 47105527)
103. Naor D, Wallach-Dayan SB, Zahalka MA i wsp. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-7.
104. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 2008;121:925-32. (Pubitemid 351639411)
105. Schmitt M, Schmitt A, Rojewski MT i wsp. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008;111:1357-65. (Pubitemid 351213422)
106. nd i wsp. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998;4:567-76. (Pubitemid 28193554)
107. Pujana MA, Han JD, Starita LM i wsp. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007;39:1338-49. (Pubitemid 350035000)
108. Assmann V, Jenkinson D, Marshall JF i wsp. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci 1999;112:3943-54. (Pubitemid 30119764)
109. Groen AC, Cameron LA, Coughlin M i wsp. XRHAMM functions in ran-dependent microtubule nucleation and pole formation during anastral spindle assembly. Curr Biol 2004;14:1801-11. (Pubitemid 39408769)
110. Maxwell CA, Rasmussen E, Zhan F i wsp. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004;104:1151-8. (Pubitemid 39038037)
111. Liu R, Wang X, Chen GY i wsp. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26. (Pubitemid 46143225)
112. Shipitsin M, Campbell LL, Argani P i wsp. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73. (Pubitemid 46349843)
113. Hamilton SR, Fard S F, Paiwand FF i wsp. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1, 2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007;282:16667-80. (Pubitemid 47100370)
114. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
115. Baumgartner G, Gomar-Hoss C, Sakr L i wsp. The impact of extracellular matrix on the chemoresistance of solid tumorsexperimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998;131:85-99. (Pubitemid 28467044)
116. Green SK, Francia G, Isidoro C i wsp. Antiadhesive antibodies targeting Ecadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004;3:149-59. (Pubitemid 39193689)
117. Spruss T, Bernhardt G, Schonenberger H i wsp. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol 1995;121:193-202.
118. Smith KJ, Skelton HG, Turiansky G i wsp. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 1997;36:239-42. (Pubitemid 27078919)
119. Klocker J, Sabitzer H, Raunik W i wsp. Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett 1998;131:113-5. (Pubitemid 28467047)
120. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000;36:193-207.
121. Cordo Russo RI, Garcia MG, Alaniz L i wsp. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 2008;122:1012-8. (Pubitemid 351213998)
122. 2+ signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:19-24. (Pubitemid 43127958)
123. Wang SJ, Bourguignon L Y W. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:771-8. (Pubitemid 44086442)
124. Ohashi R, Takahashi F, Cui R i wsp. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell ung cancer cell. Cancer Lett 2007;252:225-34. (Pubitemid 46809789)
125. Misra S, Ghatak S, Toole B P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005;280:20310-5. (Pubitemid 40776728)
126. Gilg AG, Tye SL, Tolliver LB i wsp. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin Cancer Res 2008;14:1804-13. (Pubitemid 351469467)
127. Toole B P, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008;18:244-50.
128. Bacso Z, Nagy H, Goda K i wsp. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A 2004;6:105-16. (Pubitemid 39362285)
129. Miletti-González KE, Chen S, Muthukumaran N i wsp. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005;65:6660-7. (Pubitemid 41060702)
130. Slomiany MG, Dai L, Tolliver LB i wsp. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 2009;15:7593-601.
131. Slomiany MG, Dai L, Bomar PA i wsp. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 2009;69:4992-8.
132. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008;5:474-86.
133. Ghatak S, Misra S, Toole B P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002;277:38013-20. (Pubitemid 35154652)
134. Toole B P, Ghatak S, Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 2008;9:249-52.
135. Lesley J, Hascall VC, Tammi M i wsp. Hyaluronan binding by cell surface CD44. J Biol Chem 2000;275:26967-75.
136. Zeng C, Toole B P, Kinney SD i wsp. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998;77:396-401. (Pubitemid 28299876)
137. Misra S, Ghatak S, Zoltan-Jones A i wsp. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 2003;278:25285-8. (Pubitemid 36835275)
138. West DC, Hampson IN, Arnold F i wsp. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985;228:1324-6.
139. Matou-Nasri S, Gaffney J, Kumar S i wsp. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 2009;35:761-73.
140. Cui X, Xu H, Zhou S i wsp. Evaluation of angiogenic activities of hyaluronan oligosaccharides of defined minimum size. Life Sci 2009;85:573-7.
141. Peterson RM, Yu Q, Stamenkovic I i wsp. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol 2000;156:2159-67. (Pubitemid 30641782)
142. Ahrens T, Sleeman JP, Schempp CM i wsp. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 2001;20:3399-408. (Pubitemid 32588988)
143. Mohapatra S, Yang X, Wright JA i wsp. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med 1996;183:1663-8. (Pubitemid 26134308)
144. Liu N, Lapcevich RK, Underhill CB i wsp. Metastatin: a hyaluronanbinding complex from cartilage that inhibits tumor growth. Cancer Res 2001;61:1022-8. (Pubitemid 32174420)
145. Lee H, Mok H, Lee S i wsp. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release 2007;119:245-252. (Pubitemid 46754507)
146. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46:1271-7.
147. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010;70:2455-64.
148. Wallach-Dayan SB, Rubinstein AM, Hand C i wsp. DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther 2008;7:1615-23.
149. Greiner J, Schmitt A, Giannopoulos K i wsp. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010;95:1191-7.
150. Yabushita H, Kishida T, Fusano K i wsp. Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncol Rep 2005;13:1101-5.
151. Liu N, Gao F, Han Z i wsp. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res 2001;61:5207-14. (Pubitemid 32681555)
152. Lai E, Singh R, Teng B i wsp. Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth in mice. Dis Colon Rectum 2010;53:475-82.
153. Lokeshwar VB, Lopez LE, Munoz D i wsp. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res 2010;70:2613-23.
154. Frost GI, Mohapatra G, Wong TM i wsp. HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 2000;19:870-7. (Pubitemid 30153744)
155. Jacobson A, Rahmanian M, Rubin K i wsp. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002;102:212-9. (Pubitemid 35222286)
156. Shuster S, Frost GI, Csoka AB i wsp. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer 2002;102:192-7. (Pubitemid 35168035)
157. Nykopp TK, Rilla K, Sironen R i wsp. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 2009;9:143.
158. Bouga H, Tsouros I, Bounias D i wsp. Involvement of hyaluronidases in colorectal cancer. BMC Cancer 2010;10:499.
159. Wang XY, Tan JX, Vasse M i wsp. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro. Chin Med J (Engl) 2009;122:1300-4.
160. Lokeshwar VB, Cerwinka WH, Lokeshwar BL. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 2005;65:224-50.
161. Delpech B, Laquerriere A, Maingonnat C i wsp. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res 2002;22:2423-7. (Pubitemid 34857077)
162. Enegd B, King JA, Stylli S i wsp. Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery 2002;50:1311-8. (Pubitemid 36322773)
163. Simpson MA. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in
164. Lokeshwar VB, Schroeder GL, Selzer MG i wsp. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002;95:61-72. (Pubitemid 34743483)
165. Gao F, Cao M, Yang C i wsp. Preparation and characterization of hyaluronan oligosaccharides for angiogenesis study. J Biomed Mater Res B Appl Biomater 2006;78:385-92. (Pubitemid 44167744)
166. Koyama H, Hibi T, Isogai Z i wsp. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol 2007;170:1086-99. (Pubitemid 47339375)
167. Tzuman YC, Sapoznik S, Granot D i wsp. Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins. Neoplasia 2010;12:51-60.
168. Wang YZ, Cao ML, Liu YW i wsp. CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood) 2011;236:84-90.
169. Lokeshwar VB, Obek C, Soloway MS i wsp. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997;57:773-7 (Pubitemid 27085665)
170. [errata w: Cancer Res 1998;58:3191].
171. Franzmann EJ, Schroeder GL, Goodwin WJ i wsp. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 2003;106:438-45. (Pubitemid 36870409)
172. Lokeshwar VB, Rubinowicz D, Schroeder GL i wsp. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001;276:11922-32.
173. Shibata T, Fujimoto K, Nagayama K i wsp. Inhibitory activity of brown algal phlorotannins against hyaluronidase. Int J Food Sci Tech 2002;37:703-9. (Pubitemid 36840500)
174. Katsube T, Yamasaki Y, Iwamoto M i wsp. Hyaluronidase inhibiting polysaccharide isolated and purified from hot water extract of Sporophyll of Undaria pinnatifida. Food Sci Technol Res 2003;9:25-9. (Pubitemid 37044211)
175. Chen T, Wong YS, Zheng W i wsp. Selenium nanoparticles fabricated in Undaria pinnatifida polysaccharide solutions induce mitochondriamediated apoptosis in A375 human melanoma cells. Colloids Surf B Biointerfaces 2008;67:26-31.
176. Gaffney J, Matou-Nasri S, Grau-Olivares M i wsp. Therapeutic applications of hyaluronan. Mol Biosyst 2010;6:437-43.
177. Park W, Kim KS, Bae BC i wsp. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight. Eur J Pharm Sci 2010;40:367-75.
178. Speranza A, Pellizzaro C, Coradini D. Hyaluronic acid butyric esters in cancer therapy. Anticancer Drugs 2005;16:373-9. (Pubitemid 40434603)
179. Cerroni B, Chiessi E, Margheritelli S i wsp. Polymer shelled microparticles for a targeted doxorubicin delivery in cancer therapy. Biomacromolecules 2011;12:593-601.